A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

Unknown Phase 1 NCT02277717

Study Description

The purpose of this study is to evaluate the safety of a new medicinal drug SYD985 at different dose levels in patients with cancer, to understand how SYD985 is handled by the body and to evaluate the effect of SYD985 on the cancer.

Study Details

Registry ID:
NCT02277717
Conditions:
Solid Tumors
Phase:
Phase 1
Target Enrollment:
185 participants
Start Date:
Healthy Volunteers:
No

Study Locations (15 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →